The global burden of COPD: epidemiology and effect of prevention strategies
- PMID: 40684784
- DOI: 10.1016/S2213-2600(24)00339-4
The global burden of COPD: epidemiology and effect of prevention strategies
Abstract
Chronic obstructive pulmonary disease (COPD) affects more than 400 million people, continues to be the third cause of death worldwide, and has substantial regional variations in prevalence, risk factors, and temporal trends. COPD is associated with major socioeconomic and health consequences, with low-income and middle-income countries contributing the most to its growing burden. COPD prevalence among women is projected to increase, while that among men will decrease. This difference is possibly because tobacco consumption among women is decreasing at a slower rate than among men. Also, women are more likely to be exposed to other risk factors such as biomass combustion products. Most COPD cases are preventable given the role that smoking and environmental factors play in its development. Knowledge of the causes of COPD in different areas of the globe could provide new insights to address the geographical disparity of the disease and thus make COPD prevention a reality. It is important to implement preventive health policies that might mitigate the expected increase in COPD in women in low-income and middle-income countries and have already proven successful in some regions with high prevalence of the disease. In addition, a reduction in the huge burden of underdiagnosed COPD is necessary to offer effective secondary and tertiary preventive interventions.
Copyright © 2025 Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests MMdO reports compensation for scientific lectures from Boehringer Ingelheim and GSK, outside the submitted work. BC reports compensation for participation on advisory boards and consultancy fees from GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Pulmonx, Sanofi-Aventis, Chiesi, Menarini, and Gala Therapeutics. SDA reports honoraria paid for advisory board participation and fees for lectures from Sanofi, GSK, Methapharm, and AstraZeneca. DM is a consultant to and receives fees or royalties from AstraZeneca, GSK, Chiesi, Regeneron, Genentech, Up-to-Date, and the COPD Foundation; and is an expert witness on behalf of people suing the tobacco or vaping industry. AFSA reports grants from Colt Foundation. DO reports research grants from Colt Foundation and Academy of Medical Sciences. All other authors declare no competing interests. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources